The stock price of Spero Therapeutics Inc (NASDAQ: SPRO) has jumped by 8.80 compared to previous close of 1.42. Despite this, the company has seen a gain of 8.80% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-13 that Spero Therapeutics, Inc. (SPRO) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of a loss of $0.18 per share. This compares to earnings of $0.55 per share a year ago.
Is It Worth Investing in Spero Therapeutics Inc (NASDAQ: SPRO) Right Now?
Spero Therapeutics Inc (NASDAQ: SPRO) has a higher price-to-earnings ratio of 3.64x compared to its average ratio, The 36-month beta value for SPRO is at 0.62. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SPRO is 39.15M, and currently, shorts hold a 1.31% of that float. The average trading volume for SPRO on May 02, 2024 was 320.96K shares.
SPRO’s Market Performance
SPRO stock saw a decrease of 8.80% in the past week, with a monthly decline of -14.17% and a quarterly a decrease of 1.64%. The volatility ratio for the week is 6.17%, and the volatility levels for the last 30 days are 5.95% for Spero Therapeutics Inc (SPRO). The simple moving average for the past 20 days is -0.10% for SPRO’s stock, with a 10.71% simple moving average for the past 200 days.
Analysts’ Opinion of SPRO
Many brokerage firms have already submitted their reports for SPRO stocks, with Evercore ISI repeating the rating for SPRO by listing it as a “Outperform.” The predicted price for SPRO in the upcoming period, according to Evercore ISI is $8 based on the research report published on September 23, 2022 of the previous year 2022.
H.C. Wainwright gave a rating of “Buy” to SPRO, setting the target price at $40 in the report published on January 22nd of the previous year.
SPRO Trading at -5.05% from the 50-Day Moving Average
After a stumble in the market that brought SPRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.56% of loss for the given period.
Volatility was left at 5.95%, however, over the last 30 days, the volatility rate increased by 6.17%, as shares sank -13.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.98% upper at present.
During the last 5 trading sessions, SPRO rose by +8.80%, which changed the moving average for the period of 200-days by +2.32% in comparison to the 20-day moving average, which settled at $1.5343. In addition, Spero Therapeutics Inc saw 5.10% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRO starting from Shukla Sath, who sale 45,093 shares at the price of $1.45 back on Feb 05 ’24. After this action, Shukla Sath now owns 1,176,007 shares of Spero Therapeutics Inc, valued at $65,385 using the latest closing price.
Mahadevia Ankit, the Director of Spero Therapeutics Inc, sale 63,795 shares at $1.37 during a trade that took place back on Feb 02 ’24, which means that Mahadevia Ankit is holding 744,997 shares at $87,399 based on the most recent closing price.
Stock Fundamentals for SPRO
Current profitability levels for the company are sitting at:
- 0.2 for the present operating margin
- 0.81 for the gross margin
The net margin for Spero Therapeutics Inc stands at 0.24. The total capital return value is set at 0.14. Equity return is now at value 24.95, with 14.85 for asset returns.
Based on Spero Therapeutics Inc (SPRO), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -5.95. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -20.59.
Currently, EBITDA for the company is 20.11 million with net debt to EBITDA at -3.22. When we switch over and look at the enterprise to sales, we see a ratio of 0.13. The receivables turnover for the company is 1.95for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.53.
Conclusion
In conclusion, Spero Therapeutics Inc (SPRO) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
